02:44 , Mar 10, 2018 |  BioCentury  |  Product Development

Virtual leap

Novartis AG’s decision to expand a collaboration with mobile technology and clinical trials management company Science 37 Inc. fits squarely within CEO Vasant Narasimhan’s oft-stated plans to use digital health to speed drug development. The...
17:27 , Mar 9, 2018 |  BC Week In Review  |  Company News

Novartis partners with Science 37 to conduct virtual clinical trials

Novartis AG (NYSE:NVS) and Science 37 Inc. (Los Angeles, Calif.) expanded their collaboration and will now conduct virtual Phase II and Phase III clinical studies, moving beyond the feasibility studies of the technology under their...
06:15 , Mar 7, 2018 |  BC Extra  |  Company News

Novartis expands virtual trial footprint

Novartis AG (NYSE:NVS) and Science 37 Inc. (Los Angeles, Calif.) expanded their collaboration and will now conduct virtual Phase II and Phase III clinical studies, moving beyond the feasibility studies of the technology under their...
23:56 , Nov 3, 2017 |  BioCentury  |  Strategy

Broadening Novartis’ NET

Novartis AG’s proposed acquisition of Advanced Accelerator Applications S.A. would broaden the pharma’s neuroendocrine tumor franchise by providing it with a second-line agent -- Lutathera -- that addresses patients with progressive, symptomatic disease. On Oct....
07:00 , Aug 10, 2015 |  BC Week In Review  |  Company News

Novartis sales and marketing update

Novartis said Germany’s Federal Joint Committee (G-BA) issued an early benefit assessment stating that Signifor pasireotide provides “little added benefit” for patients with acromelagy for whom surgery is not an option or has not worked...
08:00 , Jan 26, 2015 |  BC Week In Review  |  Clinical News

Signifor LAR pasireotide regulatory update

FDA approved once-monthly Signifor LAR pasireotide from Novartis to treat acromegaly in patients who have had an inadequate response to surgery and/or for whom surgery is not an option. The long-acting release formulation of Signifor...
08:00 , Dec 15, 2014 |  BC Week In Review  |  Clinical News

Once-monthly Signifor pasireotide regulatory update

The European Commission approved once-monthly Signifor pasireotide from Novartis to treat adults with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with a...
07:00 , Oct 13, 2014 |  BC Week In Review  |  Clinical News

Pasireotide regulatory update

EMA's CHMP recommended approval of Signifor LAR pasireotide from Novartis to treat acromegaly in adult patients for whom surgery is not an option or has not worked and who are inadequately controlled on treatment with...
07:00 , May 26, 2014 |  BC Week In Review  |  Clinical News

Signifor LAR pasireotide: Phase III data

A double-blind, international Phase III trial in 198 patients with inadequately controlled acromegaly showed that 40 and 60 mg Signifor LAR given every 4 weeks for 24 weeks each met the primary endpoint of a...
08:00 , Feb 17, 2014 |  BC Week In Review  |  Clinical News

Signifor LAR pasireotide regulatory update

Novartis disclosed in its 4Q13 earnings that it submitted regulatory applications in the U.S. and EU for Signifor LAR pasireotide to treat patients with acromegaly for whom medical therapy is appropriate. Signifor LAR is a...